GlassScriptPhysician profile
Shilpa Desai
NPI 1104112879
$17,290.84
in general payments reported to CMS, 2019-2025
19 companies · $519 in 2025
The $519 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $678 · 2020: $50.00 · 2021: $21.43 · 2022: $394 · 2023: $15K · 2024: $878 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,501 · Honoraria: $3,000 · Food and Beverage: $2,575 · Consulting Fee: $2,345 · Travel and Lodging: $718 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,501.00 |
| Honoraria | $3,000.00 |
| Food and Beverage | $2,575.02 |
| Consulting Fee | $2,345.00 |
| Travel and Lodging | $718.41 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $11,454.05 | 2023-2025 | Syfovre |
| Genentech, INC. | $2,486.88 | 2023-2025 | Susvimo, Vabysmo |
| Genentech USA, INC. | $489.92 | 2022-2025 | Vabysmo |
| Abbvie INC. | $475.61 | 2022-2025 | Ozurdex |
| Regeneron Healthcare Solutions, INC. | $471.18 | 2019-2025 | Eylea Hd, Eylea |
| Alimera Sciences, INC. | $463.51 | 2019-2024 | Iluvien, Yutiq |
| Alcon Vision LLC | $403.22 | 2019-2024 | Constellation, Clareon |
| Regeneron Pharmaceuticals, INC. | $367.34 | 2019-2024 | Eylea Hd |
| Astellas Pharma US INC | $276.18 | 2023-2024 | Izervay |
| Novartis Pharmaceuticals Corporation | $174.43 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $55.89 | 2024-2025 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $49.50 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $29.99 | 2025 | Xiidra |
| Ani Pharmaceuticals, INC. | $28.34 | 2025 | Yutiq |
| Biogen, INC. | $26.14 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $21.39 | 2019 | |
| Eyepoint US, INC. | $17.27 | 2023 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shilpa Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.